KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $3.7 billion.

  • Amneal Pharmaceuticals' Total Liabilities rose 436.86% to $3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 436.86%. This contributed to the annual value of $3.6 billion for FY2024, which is 458.79% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Total Liabilities stood at $3.7 billion, which was up 436.86% from $3.5 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Total Liabilities registered a high of $3.9 billion during Q2 2022, and its lowest value of $3.5 billion during Q4 2023.
  • Its 5-year average for Total Liabilities is $3.6 billion, with a median of $3.6 billion in 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Total Liabilities crashed by 988.08% in 2021 and then surged by 648.63% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Total Liabilities stood at $3.6 billion in 2021, then grew by 1.19% to $3.6 billion in 2022, then decreased by 4.5% to $3.5 billion in 2023, then rose by 4.59% to $3.6 billion in 2024, then rose by 2.74% to $3.7 billion in 2025.
  • Its last three reported values are $3.7 billion in Q3 2025, $3.5 billion for Q2 2025, and $3.5 billion during Q1 2025.